The α-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step

Molecular Pharmacology

Volumn 61, Issue 1, 2002, Pages 186-193

  Papandréou, Marie Jeanne ^a   Barbouche, Rym ^a   Guieu, Régis ^a   Kieny, Marie Paule ^b   Fenouillet, Emmanuel ^a  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; ALPHA GLUCOSIDASE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; LIGAND; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME GLYCOSYLATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOREACTIVITY; LYMPHOCYTE CULTURE; MAMMAL CELL; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR BINDING; VIRUS INHIBITION; VIRUS VIRULENCE;

1-DEOXYNOJIRIMYCIN; ALPHA-GLUCOSIDASES; ANIMALS; ANTIGENS, CD4; ANTIVIRAL AGENTS; CELLS, CULTURED; CRICETINAE; DRUG COMBINATIONS; GLYCOSYLATION; HIV; HIV ENVELOPE PROTEIN GP120; HUMANS; LIGANDS; MEMBRANE FUSION; MICE; RECEPTORS, CXCR4;

EID: 0036141030     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.1.186     Document Type: Article

References (39)

1. An anti-HIV multiple antigen peptide encompassing the cleavage region of the Env precursor interferes with membrane fusion at a post-CD4 binding step
2. Relationships between the anti-HIV V3-derived peptide SPC3 and lymphocyte membrane properties involved in virus entry: SPC3 interferes with CXCR4
3. A vaccine for HIV type 1: The antibody perspective
4. HIV gp120 V(1)/V(2) and C(2)-V(3) domains glycoprotein compatibility is required for viral replication
5. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: A possible function in viral fusion?
6. Attenuation of HIV-1 infectivity by an inhibitor of oligosaccharide processing
7. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
8. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events
9. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions
10. Maturation and assembly of retroviral glycoproteins
11. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains
12. Protein disulfide isomerase catalytic activity is required for HIV envelope-mediated membrane fusion at a post-CD4 binding step
13. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein
14. Functions of HIV envelope glycans
15. Recombinant HIV envelope expressed in an alpha glucosidase I deficient CHO cell line and its parental cell line in the presence of deoxynojirmycin is functional
16. The α-glucosidase inhibitor N-butyldeoxynojirmycin inhibits HIV entry at the level of post-CD4 binding
17. N butyldeoxynojirmycin-mediated inhibition of HIV entry correlates with changes in antibody recognition of the V1/V2 region of gp120
18. Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase
19. CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons
20. Anti-HIV drug mechanism
21. Improved antigenicity of the HIV env protein by cleavage site removal
22. The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1
23. Dissociation of the CD4 and CXCR4 binding properties of human immunodeficiency virus type1 gp120 by deletion of the first putative alpha-helical conserved structure
24. Interactions among HIV gp120, CD4, and CXCR4: Dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies
25. Role of N glycosylation in pathogenesis of HIV-1
26. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
27. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism
28. Functional characterization of the V1V2 region of human immunodeficiency virus type 1
29. Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain
30. N-Linked glycosylation of the HIV-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 co-receptor utilization
31. Glucosidase inhibitors for treatment of HIV-1 infection
32. Mechanism of action of N-butyl deoxynojirmycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs
33. Inhibition of HIV and SIV infectivity by blockade of alpha-glucosidase activity
34. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
35. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerizatian and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding
36. Inhibition of tyrosine kinase activation blocks the down-regulation of CXC chemokine receptor 4 by HIV-1 gp120 in CD4+ T cells
37. The tolerability and pharmacokinetics of N-butyl-deoxynojirmycin in patients with advanced HIV disease (ACTG 100)
38. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
39. Characterization of recombinant human CXCR4 in insect cells: Role of extracellular domains and N-glycosylation in ligand binding